[1] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
[2] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
[3] |
SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun.
Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.
|
[4] |
XU Shungui, LIU Chunguang.
Survey of the Regulation System of OTC Drugs in the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 141-144.
|
[5] |
WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei.
Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
|
[6] |
LIU Pengcheng, WANG Jiayu, CHEN Jinmin, WANG Minjiao, SHEN Mengqiu, LI Ming.
Pharmacovigilance Laws in Europe and America and Their Implications for China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 877-882.
|
[7] |
YUAN Lin, GAOYan, LU Changfei.
Preliminary Thinking on the Establishment of Pharmacovigilance System in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.
|
[8] |
LI Dan.
Overview of Incentives for Rare Disease Drugs Research and Development in the United States and Enlightenment for China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 339-342.
|
[9] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[10] |
FENG Hong-yun, WU Gui-zhi, FAN Yan, DONG Duo.
Analysis of Drug Manufacturer on Post-marketing Drug Risk Monitoring and Management Status in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 16-19.
|
[11] |
CHANG Yun-feng, HAO Lei, ZHANG Xiao-jian, LI Xue-li, GAO Han, LI Jun-shan.
To compare the quality of Schisandra formula particles from different manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 278-282.
|
[12] |
PENG Li-li, FAN Yan, LIU Wei, GUO Xue, HU Jun.
How Drug Manufacturers to Establish Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 666-670.
|
[13] |
SUN Jun, HUANG Qian-qian, GAN Ge, WANG Jia-yu.
Discussion on the Strategy of Drug Manufacturers to Deal with the Adverse Drug Event Clustering Signal
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 671-674.
|
[14] |
ZHAO Shi-dan, GAO Xu-guang, DAI Yun-peng, CAO Fei, LIU Li-min, LI Bai-qiang, LU Zhong-ping .
Preliminary Exploration for Construction of Adverse Drug Reaction/Event Sentinel Surveillance in Heilongjiang Province
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 269-271.
|
[15] |
YU Chao, XU Yu-ming, LI Xin-ling, WANG Ling, ZHOU Juan, WAN Kai-hua, XU Jin, YUAN Xin-dong .
Demand Investigation of Interconnection between Hospital Information System and National Adverse Drug Reaction Monitoring System in China
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 154-158.
|